Cargando…
ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer
SIMPLE SUMMARY: The clinical efficacy of systemic chemotherapy is limited in pancreatic cancer (PDAC) due to toxicity-dependent dose-limitations often leading to premature cessation of therapy. Targeted delivery of chemotherapeutic drugs to cancer cells, without affecting healthy nontumor cells, wil...
Autores principales: | Slapak, Etienne J., Kong, Lily, el Mandili, Mouad, Nieuwland, Rienk, Kros, Alexander, Bijlsma, Maarten F., Spek, C. Arnold |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268056/ https://www.ncbi.nlm.nih.gov/pubmed/34282781 http://dx.doi.org/10.3390/cancers13133321 |
Ejemplares similares
-
Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer
por: Slapak, Etienne J., et al.
Publicado: (2023) -
Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview
por: Slapak, Etienne J., et al.
Publicado: (2022) -
Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?
por: Slapak, Etienne J., et al.
Publicado: (2020) -
Mesoporous silica nanoparticles as a compound delivery system in zebrafish embryos
por: Sharif, Faiza, et al.
Publicado: (2012) -
Mesoporous Silica Nanoparticle-Coated Microneedle Arrays for Intradermal Antigen Delivery
por: Tu, Jing, et al.
Publicado: (2017)